Navigation Links
Cellular Dynamics International and Roche Expand Existing Cardiotoxicity Screening Agreement

MADISON, Wis., July 1 /PRNewswire/ -- Cellular Dynamics International (CDI) and Roche announced today a significant expansion of their existing agreement to test drug development candidates for their potential to cause cardiotoxicity, or damage to heart tissue. The two-year collaboration aims to enhance drug safety testing in order to bring promising therapies to patients faster.

Under this agreement, CDI will supply purified cardiomyocytes, created from induced pluripotent stem cells (iPSCs), to Roche, and the two companies will collaborate to perform various cell characterization, toxicological, and electrophysiological response experiments. The agreement also includes an ongoing cardiomyocyte supply contract post collaboration.

Embarked upon originally in March 2008 as a validation of CDI's human pluripotent stem cell technology, the expanded agreement is a testament to the success of the first phase. This next phase moves the companies toward assessing iPSC-derived cardiomyocytes as a cardiovascular safety pharmacology as well as toxicology tool.

iPSCs are adult tissue cells that have been reprogrammed to a pluripotent, embryonic-like state. Like embryonic stem cells, iPSCs have the ability to differentiate into any cell type in the body. However, because they are created from adult skin cells, not embryos, they enable patient-specific stem cells, an important factor in moving the technology toward personalized medicine.

The goal of the agreement's next phase is to detect drug-induced changes in cardiomyocyte activity across a spectrum of compounds. While it is already standard practice to perform in vitro testing of drug candidates on cardiomyocytes, the cell models currently used have a limited utility to reliably predict conduction-related effects and/or overt cardiotoxicity. CDI's iPSC-derived cardiomyocytes could overcome these limitations by providing a human-based, genetically diverse, virtually unlimited cell supply. Together these attributes provide a platform expected to streamline drug development and more accurately predict human physiological responses.

"We are thrilled with the expansion of our Roche human cardiomyocyte program," said Robert Palay, CDI Chief Executive Officer. "We view this as the next logical step in providing Roche with high quality iPSC-derived human cardiomyocytes in sufficient volumes for their drug toxicity and development needs, thereby helping to bring safe and effective medicines to patients faster."

Commenting on the expanded agreement, Chris Kendrick-Parker, CDI Chief Commercial Officer, said, "CDI well understands the limitations associated with current in vitro testing models that do not appropriately reflect the target cell population and physiology. Our iPSC technology overcomes these obstacles and offers the promise of generating differentiated cell types, even personalized cell types, from virtually any genetic background. We believe iPSC technology will play a pivotal role as drug discovery and development practices continue to evolve toward personalized therapeutics, and we are excited to be working with a world-class organization such as Roche in this endeavour."

About Cellular Dynamics International, Inc.

Cellular Dynamics International, Inc. (CDI) is a leading developer of next-generation stem cell technologies for drug development and personalized medicine applications. CDI harnesses the power of pluripotent stem cells and their ability to differentiate into any cell type for world-class drug development tools. In addition, it is the leader in iPS technology, the production of pluripotent stem cell lines from adult tissue. CDI was founded in 2004 by Dr. James Thomson, a pioneer in human embryonic stem cell research at the University of Wisconsin-Madison, and Tactics II Ventures, a Wisconsin-based venture capital fund. CDI's facilities are located in Madison, Wisconsin. See


    Cellular Dynamics International, Inc.
    Joleen Rau
    Senior Director, Marketing & Communications
    (608) 310-5142

    Tony Russo

    Robert E. Flamm, Ph.D.

SOURCE Cellular Dynamics International (CDI)
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. New Cellular Bioenergetics Workshops Series Inaugurated by Seahorse Bioscience with Two of the Worlds Leading Bioenergetics Researchers
2. MIT, BU engineer cellular circuits that count events
3. Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
4. Orange and Medic4all Launched the Worlds First Cellular Tele-Health Service
5. MaxCyte Debuts the STX Scalable Transfection System at the A/C/T Assays & Cellular Targets Meeting
6. ChanTest to Highlight the Worlds Largest Catalog of Ion Channel-Expressing Cell Lines and Discovery Services at Assays & Cellular Targets Conference, Booth 11
7. Cellumen to Collaborate With the NCTR of the FDA to Apply Cellular Systems Biology (CSB(TM)) to Predictive Toxicology
8. New insights into cellular reprogramming revealed by genomic analysis
9. Sangamo BioSciences Announces Presentation of Phase 1 Data of ZFP Therapeutic at International Society for Cellular Therapy (ISCT) Meeting
10. Having Penetrated Israels Domestic Telephony Market, 012 Smile.Communications Prepares for Its Next Goal: Entering Israels Cellular Market
11. Cellular construction methods emulated
Post Your Comments:
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... Houston Methodist Willowbrook Hospital has signed ... to serve as their official health care provider. ... will provide sponsorship support, athletic training services, and ... volunteers, athletes and families. "We are ... and to bring Houston Methodist quality services and ...
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
Breaking Biology Technology:
(Date:6/9/2016)... control systems is proud to announce the introduction of fingerprint attendance control software, allowing ... are actually signing in, and to even control the opening of doors. ... ... ... Photo - ...
(Date:6/2/2016)... YORK , June 2, 2016   The Weather ... is announcing Watson Ads, an industry-first capability in which consumers ... by being able to ask questions via voice or text ... Marketers have long sought ... the consumer, that can be personal, relevant and valuable; and ...
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
Breaking Biology News(10 mins):